The therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide. The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorthalidone. The therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone. Metformin may increase the hypoglycemic activities of Quinine. Rasagiline may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Levonorgestrel. The therapeutic efficacy of Metformin can be decreased when used in combination with Indinavir. Metformin may increase the hypoglycemic activities of Repaglinide. The therapeutic efficacy of Metformin can be decreased when used in combination with Methotrimeprazine. Metformin may increase the hypoglycemic activities of Insulin Detemir. Rosoxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Estradiol. The therapeutic efficacy of Metformin can be decreased when used in combination with Norgestimate. Furazolidone may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Insulin Glargine. Desvenlafaxine may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Glimepiride. The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone. The therapeutic efficacy of Metformin can be decreased when used in combination with Histrelin. Metformin may increase the hypoglycemic activities of Insulin Human. Oxandrolone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone. The risk or severity of adverse effects can be increased when Diclofenamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir. The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone. Metformin may increase the hypoglycemic activities of Disopyramide. Testosterone may increase the hypoglycemic activities of Metformin. Venlafaxine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Pasireotide. Indalpine may increase the hypoglycemic activities of Metformin. Sparfloxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone. Norfloxacin may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin. Pazufloxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Ethynodiol diacetate. Duloxetine may increase the hypoglycemic activities of Metformin. Prulifloxacin may increase the hypoglycemic activities of Metformin. Carbaspirin calcium may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Topiramate is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Desogestrel. Olsalazine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Pipotiazine. Flumequine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone. Metformin may increase the hypoglycemic activities of Gliclazide. Phenoxypropazine may increase the hypoglycemic activities of Metformin. Nalidixic Acid may increase the hypoglycemic activities of Metformin. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Nilotinib. Hydracarbazine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin. The therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide. Fluvoxamine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Ethanol is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroxyprogesterone caproate. Dapoxetine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib. The risk or severity of adverse effects can be increased when Diatrizoate is combined with Metformin. Nandrolone may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Mecasermin. The therapeutic efficacy of Metformin can be decreased when used in combination with Estrone sulfate. The therapeutic efficacy of Metformin can be decreased when used in combination with Corticotropin. The therapeutic efficacy of Metformin can be decreased when used in combination with Piperazine. Pirlindole may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide. Fluoxymesterone may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Nateglinide. Mesalazine may increase the hypoglycemic activities of Metformin. Escitalopram may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Clozapine. The therapeutic efficacy of Metformin can be decreased when used in combination with Cyproterone acetate. The serum concentration of Metformin can be increased when it is combined with Cimetidine. The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone. The therapeutic efficacy of Metformin can be decreased when used in combination with Etonogestrel. The therapeutic efficacy of Metformin can be decreased when used in combination with Pentamidine. Trovafloxacin may increase the hypoglycemic activities of Metformin. Brofaromine may increase the hypoglycemic activities of Metformin. Phenelzine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Iloperidone. Acetylsalicylic acid may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Brexpiprazole. Minaprine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Ethiodized oil is combined with Metformin. Harmaline may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir. Caroxazone may increase the hypoglycemic activities of Metformin. The serum concentration of Metformin can be increased when it is combined with Lamotrigine. Testosterone Propionate may increase the hypoglycemic activities of Metformin. Pheniprazine may increase the hypoglycemic activities of Metformin. Nitroaspirin may increase the hypoglycemic activities of Metformin. Moclobemide may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Niacin. Gatifloxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Tipranavir. The serum concentration of Tipiracil can be increased when it is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Buserelin. Nandrolone decanoate may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide. Mebanazine may increase the hypoglycemic activities of Metformin. Citalopram may increase the hypoglycemic activities of Metformin. Zimelidine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone. Oxymetholone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus. The risk or severity of adverse effects can be increased when Dorzolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Triamcinolone. The therapeutic efficacy of Metformin can be decreased when used in combination with Progesterone. The therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Metformin can be decreased when used in combination with Cyclopenthiazide. Cinoxacin may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Acetazolamide is combined with Metformin. Iproniazid may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir. The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone. The serum concentration of Metformin can be increased when it is combined with Cephalexin. Metformin may increase the hypoglycemic activities of Sulfamethoxazole. GLPG-0492 may increase the hypoglycemic activities of Metformin. Enoxacin may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine. Procarbazine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be increased when used in combination with Ubidecarenone. Metformin may increase the hypoglycemic activities of Tolbutamide. Lipoic Acid may increase the hypoglycemic activities of Metformin. The serum concentration of Metformin can be increased when it is combined with Glycopyrronium. Mesterolone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Atazanavir.